Due to the critical antiviral roles of NKT cells, herpes viruses have evolved strategies to antagonize this function. In vivo, NKT cells are mostly activated by lipid antigen presentation by CD1d. Previously, our studies have shown that herpes simplex virus-1 (HSV-1), a common herpes virus in humans, has evolved to down-regulate CD1d expression in antigen-presenting cells and thereby inhibiting NKT cell activation (Yuan, W. et al., Nature Immunol. 2006, 7, 835-842). Dissecting the molecular mechanism of HSV-1 evasion of CD1d antigen presentation and NKT cell function will provide novel targets for antiviral designs to improve the care for patients already latently infected with HSVs. Furthermore to break down the viral immune evasion mechanism will help to improve the immunogenecity and therefore the protection efficiency of vaccine candidates to prevent new infections. We have recently identified a HSV-1 protein kinase, US3, that collaborates with viral glycoprotein B to down-regulate CD1d expression in antigen presenting cells by suppressing CD1d recycling (Rao, P. et al., J. Virol. 2011, 85: 8093-8104; Ran, X. et al., J. Virol. 2015, 89: 6646-6655). Currently we are pursuing how US3, through its kinase activity, modulates CD1d recycling pathway at both molecular and cellular levels. Remarkably, while US3-difficient virus grows well in vitro, its replication is severely attenuated in vivo, suggesting that the evasion of the CD1d-restricted NKT cell function plays a critical role in viral pathogenesis.
An emerging research field in my lab is human-specific CD1d/NKT antigen presentation. Despite a high degree of conservation, subtle but important differences exist between the CD1d antigen presentation pathways of humans and mice. These differences may account for the minimal success of natural killer T (NKT) cell-based antitumor therapies in human clinical trials, which contrast strongly with the powerful antitumor effects in conventional mouse models. In order to study human-specific CD1d antigen presentation pathway in vivo, we have recently generated novel mouse models with CD1d/NKT system humanized (Wen, X., et al., Proc. Natl. Acad. Sci. USA 2013, 110: 2963-2968; Wen, X., et al., J. Immunol. 2015, 195: 1459-1469). Characterization of these new models and application of the models to anti-tumor research are currently ongoing.
A Viral Deamidase Targets the Helicase Domain of RIG-I to Block RNA-Induced Activation Cell Host Microbe. 2016 Dec 14; 20(6):770-784. . View in PubMed
Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection J Gen Virol. 2016 Feb; 97(2):422-34. . View in PubMed
Cell Rep. 2016 07 12; 16(2):405-418. . View in PubMed
Akt Kinase-Mediated Checkpoint of cGAS DNA Sensing Pathway Cell Rep. 2015 Oct 13; 13(2):440-9. . View in PubMed
A Subset of CD8aß+ Invariant NKT Cells in a Humanized Mouse Model J Immunol. 2015 Aug 15; 195(4):1459-69. . View in PubMed
Herpes Simplex Virus 1 US3 Phosphorylates Cellular KIF3A To Downregulate CD1d Expression J Virol. 2015 Jul; 89(13):6646-55. . View in PubMed
Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment Pathogens. 2014 Jul 03; 3(3):563-76. . View in PubMed
Humanizing mice for the identification of novel anticancer lipids targeting iNKT cells Oncoimmunology. 2013 Aug 01; 2(8):e25475. . View in PubMed
Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells Proc Natl Acad Sci U S A. 2013 Feb 19; 110(8):2963-8. . View in PubMed
Herpes simplex virus 1 glycoprotein B and US3 collaborate to inhibit CD1d antigen presentation and NKT cell function J Virol. 2011 Aug; 85(16):8093-104. . View in PubMed